Finanzen von INmune Bio Inc (INMB)INMBINmune Bio Inc

Evaluating the bottom line, INmune Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -74.82%, provide a clear picture of how effectively INMB converts its operational activities into shareholder value.

In the context of the broader market, INMB competes directly with industry leaders such as ZYBT and BCTX. With a market capitalization of $34.68M, it holds a significant position in the sector. When comparing efficiency, INMB's gross margin of N/A stands against ZYBT's 20.51% and BCTX's N/A. Such benchmarking helps identify whether INmune Bio Inc is trading at a premium or discount relative to its financial performance.

INmune Bio has reported a significant reduction in net loss for Q2, down to $1.27 million from $24.46 million in the prior year. However, the company has not generated substantial revenue, with total revenue of only $50,000 in Q1 2025 and no revenue in subsequent quarters. The gross margin is currently at 100% for the earlier quarters, but it drops to 0% in 2026, indicating potential financial instability.